Design and synthesis of Thieno[3, 2- b ]pyridinone derivatives exhibiting potent activities against Mycobacterium tuberculosis in vivo by targeting Enoyl-ACP reductase

Lihong Liang,Zhiyong Liu,Jie Chen,Qin Zha,Yihuan Zhou,Jun Li,Yangbo Hu,Xinwen Chen,Tianyu Zhang,Niuniu Zhang
DOI: https://doi.org/10.1016/j.ejmech.2024.116806
IF: 7.088
2024-09-15
European Journal of Medicinal Chemistry
Abstract:In this study, a series of novel thieno [3, 2- b ]pyridinone derivatives were designed and synthesized using a scaffold hopping strategy. Six compounds showed potent anti-mycobacterial activity (minimum inhibitory concentration (MIC) ≤ 1 μg/mL) against Mycobacterium tuberculosis (Mtb) UAlRa. Compound 6c displayed good activity against Mtb UAlRv (MIC = 0.5–1 μg/mL). Compounds 6c and 6i also showed activity against Mtb UAlRa in macrophages and exhibited low cytotoxicity against LO-2 cells. The selected compounds displayed a narrow antibacterial spectrum, with no activity against representative Gram-positive, Gram-negative bacteria, as well as fungi. Furthermore, compound 6c demonstrated favorable oral pharmacokinetic properties with a T 1/2 value of 47.99 h and exhibited good in vivo activity in an acute mouse model of tuberculosis (TB). The target of compound 6c was identified as a NADH-dependent enoyl-acyl carrier protein reductase (InhA) by genome sequencing of spontaneously compound 6c -resistant Mtb mutants, indicating that compound 6c may not require activation and can directly target InhA. In vitro antimicrobial assays against a recombinant M. smegmatis overexpressing the Mtb-InhA, along with InhA inhibition assays, confirmed that InhA is the target of thieno [3, 2- b ]pyridinone derivatives. Overall, this study identified thieno [3, 2- b ]pyridinone scaffold as a novel chemotype that is promising for the development of anti-TB agents.
chemistry, medicinal
What problem does this paper attempt to address?